Daniel Murman, MD
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,181 of the $1,728 with a category attached, or 68.4%. Biogen accounts for 82.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $1,191 and has fallen 93.3% since, to $80 in 2025.
Across 8 payments — averaging $215.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- Genentech USA, Inc.$150
- F. Hoffmann-la Roche AG$80
- Eisai Inc.$73
Across 68 payments — averaging $38,122 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1M
- Genentech, Inc.$636K
- Novartis$466K
- Eli Lilly$424K
- Functional Neuromodulation Inc$42K
- H. Lundbeck A S$154
What the payments were for
- Consulting fees$1,18168%
- Food & beverage$43725%
- Education$1106%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 5 | $1,425 |
| Genentech USA, Inc. | 1 | $150 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Eisai Inc. | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADUHELM$134
How this compares
$1,728 in reported general payments places this provider in the 55th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 178 | $21,538 |
| Memantine Hcl | 675 | $16,737 |
| Rivastigmine | 49 | $7,412 |
| Donepezil Hcl | 741 | $7,244 |
| Memantine Hcl ErMemantine Hcl | 88 | $4,904 |
| Sertraline Hcl | 362 | $2,095 |
| Mirtazapine | 106 | $1,779 |
| Escitalopram Oxalate | 174 | $1,458 |
| Buspirone Hcl | 51 | $1,120 |
| Galantamine Hbr | 17 | $975 |
| Trazodone Hcl | 167 | $968 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 54 | $882 |
| Duloxetine Hcl | 44 | $847 |
| Quetiapine Fumarate | 51 | $748 |
| Lamotrigine | 48 | $664 |
Paid to pharmacies, not to this prescriber.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Erin SmithOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.